An adult with non-radiographic axial spondyloarthritis has MRI sacroiliitis, BASDAI 5.0 and spinal-pain VAS 5.5 cm despite NSAIDs and unsuitable TNF inhibition. At week 16, BASDAI falls to 3.1 and VAS to 3.0 cm. Should upadacitinib continue?AContinue because the spinal-pain VAS fell by more than 2 cmBStop because the BASDAI response criterion is not metCContinue because the BASDAI and VAS reductions sum to more than 4DStop because the spinal-pain VAS response criterion is not metEContinue because MRI inflammation removes the week-16 stopping ruleCheck my answer